TNF and inflammatory bowel disease: Interestingly, the actual British Society of Gastroenterology consensus guidelines on the management on inflammatory bowel disease in adults from 2019 recommends discontinuation of anti-TNF-treatment, especially in CD, 6–8 weeks for IFX and 4 weeks for ADA before electively planned surgery [17], whereas the actual ECCO (European Crohn’s and Colitis Organization) guidelines state that cessation of anti-TNF therapy, as well as vedolizumab or ustekinumab is not mandatory prior to surgery [18].